COMPASS PATHWAYS PLC, 10-Q filed on 8/5/2026
Quarterly Report
v3.26.1
Cover - shares
6 Months Ended
Jun. 30, 2026
Jul. 30, 2026
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2026  
Document Transition Report false  
Entity File Number 001-39522  
Entity Registrant Name COMPASS Pathways plc  
Entity Incorporation, State or Country Code X0  
Entity Address, Address Line One 33 Broadwick Street  
Entity Address, City or Town London  
Entity Address, Postal Zip Code W1F 0DQ  
Entity Address, Country GB  
City Area Code 716  
Local Phone Number 676-6461  
Title of 12(b) Security American Depositary Shares, each representing one ordinary share, par value of £0.008 per share  
Trading Symbol CMPS  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   138,476,822
Entity Central Index Key 0001816590  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
CURRENT ASSETS:    
Cash and cash equivalents $ 433,295 $ 149,608
Restricted cash 425 379
Prepaid expenses and other current assets 41,954 41,503
Total current assets 475,674 191,490
NON-CURRENT ASSETS:    
Operating lease right-of-use assets 3,937 3,424
Deferred tax assets 4,555 3,751
Long-term prepaid expenses and other assets 20,395 11,684
Total assets 504,561 210,349
CURRENT LIABILITIES:    
Accounts payable 12,240 15,222
Accrued expenses and other liabilities 15,701 9,214
Debt, current portion 0 17,523
Operating lease liabilities - current 1,885 2,110
Warrant liabilities 337,459 203,726
Total current liabilities 367,285 247,795
NON-CURRENT LIABILITIES:    
Debt, non-current portion 50,727 14,110
Operating lease liabilities - non-current 2,016 1,292
Total liabilities 420,028 263,197
Commitments and contingencies (Note 9)
SHAREHOLDERS' EQUITY/(DEFICIT):    
Ordinary shares, £0.008 par value; 135,722,306 and 96,085,785 shares authorized, issued and outstanding at June 30, 2026 and December 31, 2025, respectively 1,401 973
Additional paid-in capital 1,083,059 783,562
Accumulated other comprehensive loss (14,741) (14,789)
Accumulated deficit (985,186) (822,594)
Total shareholders' equity/(deficit) 84,533 (52,848)
Total liabilities and shareholders' equity/(deficit) $ 504,561 $ 210,349
v3.26.1
Condensed Consolidated Balance Sheets (Parenthetical) - £ / shares
Jun. 30, 2026
Dec. 31, 2025
Statement of Financial Position [Abstract]    
Common stock, par value (in GBP per share) £ 0.008 £ 0.008
Common stock, authorized (in shares) 135,722,306 96,085,785
Common stock, issued (in shares) 135,722,306 96,085,785
Common stock, outstanding (in shares) 135,722,306 96,085,785
v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
OPERATING EXPENSES:        
Research and development $ 29,175 $ 30,325 $ 55,655 $ 61,205
General and administrative 23,197 12,608 39,621 31,344
Total operating expenses 52,372 42,933 95,276 92,549
Loss from operations: (52,372) (42,933) (95,276) (92,549)
OTHER (EXPENSE) INCOME, NET:        
Fair value change of warrant liabilities (205,577) (2,540) (74,661) 16,920
Interest income 3,744 1,898 6,163 4,284
Benefit from R&D tax credit 2,583 4,287 5,060 12,735
Interest expense (1,483) (1,151) (2,948) (2,275)
Foreign exchange (losses) gains (904) 2,349 (1,640) 4,482
Other income (expense) 546 (176) 1,030 627
Total other (expense) income, net (201,091) 4,667 (66,996) 36,773
Loss before income taxes (253,463) (38,266) (162,272) (55,776)
Income tax expense (331) (137) (320) (491)
Net loss $ (253,794) $ (38,403) $ (162,592) $ (56,267)
Net loss per share attributable to ordinary shareholders: basic (in dollars per share) $ (1.88) $ (0.41) $ (1.33) $ (0.62)
Net loss per share attributable to ordinary shareholders: diluted (in dollars per share) $ (1.88) $ (0.41) $ (1.33) $ (0.62)
Weighted average ordinary shares outstanding: basic (in shares) 135,039,810 93,341,594 122,679,123 91,278,385
Weighted average ordinary shares outstanding: diluted (in shares) 135,039,810 93,341,594 122,679,123 91,278,385
Other comprehensive income:        
Foreign exchange translation adjustment $ 54 $ 1,729 $ 48 $ 1,612
Comprehensive loss $ (253,740) $ (36,674) $ (162,544) $ (54,655)
v3.26.1
Condensed Consolidated Statements of Shareholders’ Equity / (Deficit) - USD ($)
$ in Thousands
Total
At-The-Market Offering
ADDITIONAL PAID-IN CAPITAL
ADDITIONAL PAID-IN CAPITAL
At-The-Market Offering
ACCUMULATED OTHER COMPREHENSIVE LOSS
ACCUMULATED DEFICIT
Ordinary shares
ORDINARY SHARES
Ordinary shares
ORDINARY SHARES
At-The-Market Offering
Beginning balance (in shares) at Dec. 31, 2024             68,552,215  
Beginning balance at Dec. 31, 2024 $ 154,695   $ 704,919   $ (16,194) $ (534,732) $ 702  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of ordinary shares, net of issuance costs (in shares)             24,014,728  
Issuance of ordinary shares, net of issuance costs 54,816   54,583       $ 233  
Exercise of share options (in shares)             164,422  
Exercise of share options 2           $ 2  
Issuance of ordinary shares to settle vested restricted stock units (in shares)             116,961  
Issuance of ordinary shares to settle vested restricted stock units 0   (1)       $ 1  
Share-based compensation expense 3,935   3,935          
Unrealized gain (loss) on foreign currency translation (117)       (117)      
Net loss (17,864)         (17,864)    
Ending balance (in shares) at Mar. 31, 2025             92,848,326  
Ending balance at Mar. 31, 2025 195,467   763,436   (16,311) (552,596) $ 938  
Beginning balance (in shares) at Dec. 31, 2024             68,552,215  
Beginning balance at Dec. 31, 2024 154,695   704,919   (16,194) (534,732) $ 702  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Unrealized gain (loss) on foreign currency translation 1,612              
Net loss (56,267)              
Ending balance (in shares) at Jun. 30, 2025             93,586,348  
Ending balance at Jun. 30, 2025 162,555   767,190   (14,582) (590,999) $ 946  
Beginning balance (in shares) at Mar. 31, 2025             92,848,326  
Beginning balance at Mar. 31, 2025 195,467   763,436   (16,311) (552,596) $ 938  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Exercise of share options (in shares)             682,682  
Exercise of share options 9   2       $ 7  
Issuance of ordinary shares to settle vested restricted stock units (in shares)             9,375  
Issuance of ordinary shares to settle vested restricted stock units 0              
Issuance of ordinary shares under the employee share purchase plan (in shares)             45,965  
Issuance of ordinary shares under the employee share purchase plan 157   156       $ 1  
Share-based compensation expense 3,596   3,596          
Unrealized gain (loss) on foreign currency translation 1,729       1,729      
Net loss (38,403)         (38,403)    
Ending balance (in shares) at Jun. 30, 2025             93,586,348  
Ending balance at Jun. 30, 2025 $ 162,555   767,190   (14,582) (590,999) $ 946  
Beginning balance (in shares) at Dec. 31, 2025 96,085,785           96,085,785  
Beginning balance at Dec. 31, 2025 $ (52,848)   783,562   (14,789) (822,594) $ 973  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of ordinary shares, net of issuance costs (in shares)             17,500,000  
Issuance of ordinary shares, net of issuance costs 131,286   131,097       $ 189  
Exercise of share options (in shares)             6,333  
Exercise of share options 24   23       $ 1  
Issuance of ordinary shares to settle vested restricted stock units (in shares)             170,558  
Issuance of ordinary shares to settle vested restricted stock units 0   (2)       $ 2  
Issuance of ordinary shares to settle warrant exercised (in shares)             21,160,619  
Issuance of ordinary shares to settle warrant exercised 154,133   153,905       $ 228  
Share-based compensation expense 2,896   2,896          
Unrealized gain (loss) on foreign currency translation (6)       (6)      
Net loss 91,202         91,202    
Ending balance (in shares) at Mar. 31, 2026             134,923,295  
Ending balance at Mar. 31, 2026 $ 326,687   1,071,481   (14,795) (731,392) $ 1,393  
Beginning balance (in shares) at Dec. 31, 2025 96,085,785           96,085,785  
Beginning balance at Dec. 31, 2025 $ (52,848)   783,562   (14,789) (822,594) $ 973  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Unrealized gain (loss) on foreign currency translation 48              
Net loss $ (162,592)              
Ending balance (in shares) at Jun. 30, 2026 135,722,306           135,722,306  
Ending balance at Jun. 30, 2026 $ 84,533   1,083,059   (14,741) (985,186) $ 1,401  
Beginning balance (in shares) at Mar. 31, 2026             134,923,295  
Beginning balance at Mar. 31, 2026 326,687   1,071,481   (14,795) (731,392) $ 1,393  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of ordinary shares, net of issuance costs (in shares)               108,000
Issuance of ordinary shares, net of issuance costs   $ 1,397   $ 1,396       $ 1
Exercise of share options (in shares)             136,883  
Exercise of share options 1,127   1,126       $ 1  
Issuance of ordinary shares to settle vested restricted stock units (in shares)             9,375  
Issuance of ordinary shares to settle vested restricted stock units 0              
Issuance of ordinary shares under the employee share purchase plan (in shares)             29,753  
Issuance of ordinary shares under the employee share purchase plan 160   160          
Issuance of ordinary shares to settle warrant exercised (in shares)             515,000  
Issuance of ordinary shares to settle warrant exercised 5,114   5,108       $ 6  
Share-based compensation expense 4,027   4,027          
Shares tendered for withholding taxes (239)   (239)          
Unrealized gain (loss) on foreign currency translation 54       54      
Net loss $ (253,794)         (253,794)    
Ending balance (in shares) at Jun. 30, 2026 135,722,306           135,722,306  
Ending balance at Jun. 30, 2026 $ 84,533   $ 1,083,059   $ (14,741) $ (985,186) $ 1,401  
v3.26.1
Condensed Consolidated Statements of Shareholders’ Equity / (Deficit) (Parenthetical) - £ / shares
Jun. 30, 2026
Mar. 31, 2026
Dec. 31, 2025
Mar. 31, 2025
Common stock, par value (in GBP per share) £ 0.008   £ 0.008  
Ordinary shares        
Common stock, par value (in GBP per share) £ 0.008 £ 0.008 £ 0.008 £ 0.008
v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 34 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net loss $ (253,794) $ 91,202 $ (38,403) $ (17,864) $ (162,592) $ (56,267)    
Adjustments to reconcile net loss to net cash used in operating activities                
Depreciation         0 195    
Non-cash interest expense         513 768    
Non-cash gain on foreign currency remeasurement         (1,396) (1,885)    
Non-cash share-based compensation expense         6,923 7,531    
Non-cash lease expenses         1,032 1,169    
Transaction costs allocated to warrants         643 5,778    
Fair value change of warrant liabilities 205,577   2,540   74,661 (16,920)    
Changes in operating assets and liabilities                
Prepaid expenses and other current assets         (981) (14,369)    
Deferred and prepaid tax assets         (804) (515)    
Other assets         (9,030) (1,445)    
Operating lease liabilities         (1,047) (1,174)    
Accounts payable         (2,820) (2,337)    
Accrued expenses and other liabilities         6,656 (4,875)    
Net cash used in operating activities         (88,242) (84,346)    
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from conversion of ADS warrants into pre-funded warrants         115,333 0    
Payments of tax withholdings on stock award         (239) 0    
Proceeds from issuance of shares under the employee share purchase plan         160 157    
Net proceeds from issuance of long term debt         18,582 0    
Proceeds from exercise of options         1,151 11    
Proceeds from issuance of pre-funded warrants associated with the 2025 Offering, net of issuance costs         1 0    
Net cash provided by financing activities         370,013 140,525    
Effect of exchange rate changes on cash, cash equivalents and restricted cash         1,962 611    
Net increase in cash, cash equivalents and restricted cash         283,733 56,790    
Cash, cash equivalents and restricted cash, beginning of the period   $ 149,987   $ 165,470 149,987 165,470    
Cash, cash equivalents and restricted cash, end of the period 433,720   222,260   433,720 222,260 $ 433,720  
Supplemental Cash Flow Elements [Abstract]                
Cash and cash equivalents 433,295   221,881   433,295 221,881 433,295 $ 149,608
Restricted cash 425   379   425 379 425 379
Total cash, cash equivalents and restricted cash $ 433,720   $ 222,260   433,720 222,260 433,720 $ 149,987
2026 Offering                
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from Issuance of Common Stock         140,643 140,357    
At-The-Market Offering                
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from Issuance of Common Stock         1,397 0    
ADS Warrants                
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from the exercise of warrants         87,871 0    
PIPE Warrants                
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from the exercise of warrants         $ 5,114 $ 42,400  
v3.26.1
Nature of Business
6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business
1. Nature of Business
Compass Pathways plc, or the Company, is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. The Company is developing its investigational COMP360 psilocybin treatment for patients with treatment-resistant depression, or TRD, and post-traumatic stress disorder, or PTSD.
The Company is subject to risks and uncertainties common to clinical stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary intellectual property and technology, compliance with government regulations and the ability to secure additional capital to fund operations. The therapeutic candidate currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s therapeutic development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from sales. The Company has funded its operations primarily with proceeds from the sale of its ordinary shares and ADSs in public and private equity offerings, including in its offerings pursuant to its at-the-market, or ATM, offering program, and proceeds from a loan agreement with Hercules, or the Hercules Loan Agreement.
The Company has incurred recurring losses since its inception, including net losses of $162.6 million and $56.3 million for the six months ended June 30, 2026 and 2025, respectively. In addition, as of June 30, 2026, the Company had an accumulated deficit of $985.2 million. The Company expects to continue to generate operating losses until such time as we can generate revenue from sales of COMP360 or other therapeutic candidates sufficient to sustain profitability, if ever. The Company believes the cash and cash equivalents on hand as of June 30, 2026 of $433.3 million will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next twelve months from the date of issuance of these condensed consolidated financial statements. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company’s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. The Company may raise additional capital through a combination of equity offerings, debt financings, collaborations, and other strategic transactions, including marketing, distribution or licensing arrangements. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial conditions.
Market volatility, geopolitical tensions or instability (including from the effects of announced or future tariff increases), geopolitical conflict (such as the war between Ukraine and Russia and conflict in the Middle East), fluctuating inflation and interest rates and the related impact on U.S., UK and global economies, the risk of an economic slowdown or recession in the U.S., significant changes in U.S. policies or regulatory environment or the disruption to U.S. government agencies or other factors could adversely impact the Company’s operations, financial results and ability to raise additional funding.
v3.26.1
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2025, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company’s financial position for the reported periods.
The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2025, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K that was filed with the SEC, on March 24, 2026. The condensed consolidated balance sheet at December 31, 2025, was derived from audited annual consolidated financial statements but does not contain all of the footnote disclosures from the annual financial statements.
Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.
Significant Accounting Policies
The Company’s significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, warrant liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.
Recently Issued Accounting Pronouncements
In November 2024, the FASB issued ASU 2024-03 - Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, designed to improve disclosures, primarily through increased expense disaggregation. Additionally, in January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. The guidance is effective for all fiscal years beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on the Company’s consolidated financial statement disclosures.
v3.26.1
Fair Value of Financial Assets and Liabilities
6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Fair Value of Financial Assets and Liabilities
3. Fair Value of Financial Assets and Liabilities
The following tables present information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:
Fair Value Measurements
as of June 30, 2026
Level 1Level 2Level 3Total
Assets:
Cash equivalents - money market funds$195,032 $— $— $195,032 
$195,032 $— $— $195,032 
Liabilities:
Pre-funded Warrants
$— $337,459 $— $337,459 
$— $337,459 $— $337,459 
Fair Value Measurements
as of December 31, 2025
Level 1
Level 2
Level 3
Total
Assets:
Cash equivalents - money market funds$43,053 $— $— $43,053 
$43,053 $— $— $43,053 
Liabilities:
Pre-funded Warrants
$— $60,029 $— $60,029 
2025 ADS Warrants
— — 143,697 143,697 
$— $60,029 $143,697 $203,726 
During the three and six months ended June 30, 2026, there were no transfers between Level 1, Level 2 and Level 3. Excluded from the tables above, is $0.4 million and $60.8 million, as of June 30, 2026 and December 31, 2025, respectively,
of cash held in notice accounts of less than 90 days, for which the carrying value approximates fair value due to the short-term nature.
The Pre-funded Warrants and 2025 ADS Warrants are accounted for as liabilities in accordance with ASC 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40”), as both warrants contain contingent exercise provisions that do not meet the requirements of the indexation guidance under ASC 815-40 and could require the Company to pay cash to settle the warrants. The warrants are presented within warrant liabilities in the accompanying condensed consolidated balance sheets. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within the condensed consolidated statements of operations and comprehensive loss.
The Pre-funded Warrants are considered to be Level 2 in the fair value hierarchy as the inputs used to determine fair market value are observable against the Company’s stock price. The 2025 ADS Warrant are considered to be Level 3 in the fair value hierarchy as they have been recorded at fair value using the Black-Scholes model, using unobservable assumptions that have been probability-weighted for specified data milestones. As of June 30, 2026, the 2025 ADS Warrants were fully exercised.
The following table reflects the fair value of the Company’s warrant liabilities for the six months ended June 30, 2026:
Pre-Funded Warrants
ADS Warrants
Fair value as of December 31, 2025
$60,029 $143,697 
Change in fair value of warrant liabilities140,965(66,304)
Exercise of 2025 Financing pre-funded warrant liabilities(33,719)(32,542)
Issuance of February 2026 Offering of pre-funded warrants10,000—
Conversion of 2025 Financing ADS warrants to pre-funded warrants160,184(44,851)
Fair value as of June 30, 2026
$337,459 $— 
v3.26.1
Prepaid Expenses and Other Current Assets
6 Months Ended
Jun. 30, 2026
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Current Assets
4. Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following (in thousands):
June 30,December 31,
20262025
UK R&D tax credit
$15,155 $15,387 
Prepaid research and development16,074 17,102 
Prepaid income tax 2,600 3,434 
Other current assets8,125 5,580 
$41,954 $41,503 
For the years ended December 31, 2023 to 2025, the Company is uncertain whether it met the R&D intensity condition and is eligible for the enhanced effective rate due to uncertainties over whether impairments on intercompany loans and investments in subsidiary companies should be taken into account in determining the R&D intensity threshold. This matter is currently under discussion with His Majesty’s Revenue and Customs, or HMRC, and the outcome is unknown. Given the uncertainty over the outcome of the discussions with HMRC, the enhanced R&D credits as a research intensive company have not been reflected in the financial statements. If the Company reaches a successful conclusion with HMRC, additional credits of $4.1 million in the year ended December 31, 2023, $7.0 million in the year ended December 31, 2024 and $7.3 million in the year ended December 31, 2025 could be claimed.
v3.26.1
Debt
6 Months Ended
Jun. 30, 2026
Debt Disclosure [Abstract]  
Debt
5. Debt
On June 30, 2023, the Company entered into a loan agreement with Hercules, which provided for aggregate maximum borrowings of up to $50.0 million, including a term loan of $30.0 million, which was funded on June 30, 2023. On January 5, 2026, or the Effective Date, the Company entered into a third amendment to the loan agreement with Hercules, or the Loan Agreement. The Loan Agreement provides for five tranches of term loans in an aggregate principal amount of up to $150.0 million, consisting of (i) a term loan of $50.0 million, which was funded on the Effective Date, (ii) term loans of up to $30.0 million subject to achievement of a milestone relating to certain FDA approvals being granted, (iii) term loans of up to $20.0 million subject to achievement of a specified commercial milestone, and (iv) term loans of up to $20.0 million, plus the $30.0 million that became available to us upon achievement of a specified clinical milestone and any remaining unborrowed amounts from the earlier tranches, subject to the approval of Hercules’ investment committee. If the conditions of each term
loan are met, these tranches may be borrowed in drawings of a minimum of $5.0 million each. As required by the Amended Loan Agreement, a portion of the proceeds from the Tranche 1 Advance was used to repay the outstanding principal amounts and PIK due under the second amendment to the original loan Agreement, which is approximately $31.1 million.
Borrowings under the Amended Loan Agreement bear interest at an annual rate equal to the greater of (i) 9.75% or (ii) 2.75% plus the Wall Street Journal prime rate. Payments under the Amended Loan Agreement are interest only until the first principal payment is due in the first quarter of 2029, and may be deferred if the Borrowers achieve certain milestones until the scheduled maturity date on January 5, 2031. The carrying value of the Company’s outstanding debt approximates fair value, as it reflects interest rates currently available to the Company, and is classified as a Level 2 liability within the fair value hierarchy.
The Company determined that the third amendment represented a modification of debt under ASC 470-50 Debt – Modification and Extinguishment. As a result, lender fees associated with the modification were capitalized as an adjustment to the carrying amount of the debt and are being amortized over the remaining term of the instrument.
The Company incurred fees and transaction costs totaling $3.3 million associated with the initial term loan, which are recorded as a reduction to the carrying value of the long-term debt in the condensed consolidated balance sheets. These fees included $0.4 million of facility fees, $0.8 million of company fees, $0.7 million in warrants. In addition, the Company incurred $1.4 million of end of term charges, which are recorded as a debt discount and amortized to interest expense over the term of the loan.
The Company incurred fees and transactions costs totaling $4.2 million associated with the third amendment to the Loan Agreement, including $0.3 million of facility fees. In addition, the Company incurred $3.9 million of end of term charges, which are recorded as a debt discount and amortized to interest expense over the term of the loan.
The fees, transaction costs, and the end of term charges are amortized to interest expense through the maturity date using the effective interest method. The effective interest rate of the Amended Loan Agreement was 12.9% as of June 30, 2026.
In 2023, the Company issued warrants to Hercules to purchase the Company’s Ordinary Shares equal to the quotient derived by dividing (i) the amount equal to (a) 2.5% times (b) the aggregate principal amount of term loan advances made and funded under the Loan Agreement by (ii) the exercise price of the warrants. Upon receipt of the first term loan in June 2023, 94,222 shares became exercisable to Hercules with a fair market value of $0.7 million.
The Amended Loan Agreement includes a financial covenant requiring us to maintain cash equal to at least fifty-five percent of the outstanding debt balance during the period commencing on October 1, 2027 (subject to adjustment if certain performance milestones are met). If the Company meets the performance milestones, the minimum cash covenant will not apply if its market capitalization is at least $850.0 million. The Company was in compliance with all covenants of the Amended Loan Agreement as of June 30, 2026 and December 31, 2025.
Long-term debt consisted of the following (in thousands):
June 30,December 31,
20262025
Term loan payable$50,000 $30,000 
End of term charge5,300 1,425 
Future principal payments and end of term charge$55,300 $31,425 
PIK interest payable— 1,088 
Unamortized debt issuance costs(4,573)(880)
Carrying value of long-term debt$50,727 $31,633 
Less: current portion
$— $(17,523)
Non-current portion
$50,727 $14,110 
Future principal payments, including End of Term Charge, are as follows (in thousands):
December 31, 2026$— 
December 31, 20271,425 
December 31, 2028— 
December 31, 202921,674 
December 31, 203025,975 
December 31, 20316,226 
Total$55,300 
Interest expense associated with the Loan Agreement for the six months ended June 30, 2026 and 2025 was $2.9 million and $2.3 million, respectively.
v3.26.1
Shareholders’ Equity/(Deficit)
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Shareholders’ Equity/(Deficit)
6. Shareholders’ Equity/(Deficit)
Ordinary Shares
Each ordinary share entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders. Ordinary shareholders are entitled to receive dividends, if any, as may be declared by the board of directors. Through June 30, 2026, no cash dividends had been declared or paid by the Company.
At-the-Market Facility
On October 8, 2021, the Company entered into a Sales Agreement with TD Securities (USA) LLC, or TD Cowen, under which the Company was permitted to issue and sell from time to time up to $150.0 million of its ADSs, each representing one ordinary share, through TD Cowen as the sales agent. Pursuant to the Sales Agreement dated October 8, 2021, through February 27, 2025, we sold 5,491,836 ADSs under our ATM offering program, resulting in $54.8 million in net proceeds. On February 27, 2025, the Company entered into a new Sales Agreement under which the Company may issue and sell from time to time up to $150.0 million of our ADSs, subject to the terms of the Sales Agreement. Sales of the Company’s ADSs, if any, will generally be made at market prices. Pursuant to the Sales Agreement dated February 27, 2025, through June 30, 2026, the Company sold 108,000 ADSs under the Company’s ATM offering program at an average price of $13.2649 per ADS, result in gross and net proceeds of $1.4 million.
Warrants
Equity-classified
On June 30, 2023, the Company entered into a Warrant Agreement with Hercules, which provides Hercules with the right to purchase a number of the Company’s Ordinary Shares, equal to the quotient derived by dividing (i) the amount equal to (a) 2.5% times (b) the aggregate principal amount of term loan advances made and funded under the Loan Agreement by (ii) the exercise price. Upon receipt of each term loan, the Warrant will automatically become exercisable and will expire in 10 years (on June 30, 2033). On June 30, 2023, with the receipt of the first term loan, 94,222 shares became exercisable to Hercules with a fair market value of $0.7 million.
On August 18, 2023, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell and issue in a private placement transaction, or a PIPE, (i) 16,076,750 ADSs, and (ii) PIPE Warrants to purchase up to 16,076,750 ADSs, at a purchase price of approximately $7.78 per ADS ,and accompanying PIPE Warrant to purchase one ADS. Each PIPE Warrant has an exercise price of $9.93 per ADS and is exercisable for a three-year period beginning in February 2024. The PIPE Warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying the PIPE Warrants. As of June 30, 2026, PIPE Warrants had been exercised for an aggregate of 4,267,050 ADSs, resulting in proceeds of $42.4 million. During the six-months ended June 30, 2026, PIPE Warrants were exercised for an aggregate of 515,000 ADSs, resulting in proceeds of $5.1 million. The Company may receive up to an additional approximately $117.3 million in gross proceeds if the PIPE Warrants are fully exercised for cash.
Liability-classified
On January 13, 2025, in connection with the 2025 Financing, the Company issued and sold (i) 24,014,728 ADSs, each representing one ordinary share, nominal value £0.008 each, of the Company and accompanying warrants to purchase up to 24,014,728 ADSs, and (ii) in lieu of ADSs, to certain investors, Pre-funded Warrants to purchase up to 11,044,720 ADSs and accompanying 2025 ADS Warrants to purchase up to 11,044,720 ADSs. The offering prices was $4.2750 per ADS and accompanying 2025 ADS Warrant, and $4.2649 per Pre-funded Warrant and accompanying 2025 ADS Warrant. The Pre-
funded Warrants have an exercise price of $0.0001 per ADS and are exercisable immediately. The Pre-funded Warrants expire when exercised in full. The 2025 ADS Warrants had an exercise price of $5.7960 per ADS.
The 2025 Financing comprising of ADSs, Pre-funded Warrants and 2025 ADS Warrants, resulted in aggregate proceeds of $149.8 million, with issuance costs of $9.4 million. Since the Pre-funded Warrants and 2025 ADS Warrants have been classified as a liability and recorded at fair value with changes in fair value recorded in the condensed consolidated statements of operations and comprehensive loss, the aggregate proceeds have been allocated first to these warrants at their respective fair values at the issuance date. The residual has been allocated to the ADSs issued as part of the 2025 Financing and recognized within equity.
In February 2026, 35,059,448 2025 ADS Warrants were exercised and the Company received net proceeds of $203.2 million. Upon exercise of these outstanding warrants, the Company issued 15,160,619 ADSs and in lieu of ADSs, to certain institutional investors, Pre-funded Warrants to purchase up to 19,898,829 ADSs. During the three-months ended March 31, 2026, 6,000,000 Pre-funded Warrants were exercised resulting in a $33.7 million reduction in warrant liabilities. As of June 30, 2026, 23,848,829 Pre-funded Warrants remain outstanding.
On February 19, 2026, the Company issued and sold in an underwritten offering, or the February 2026 Offering, 17,500,000 ADSs at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, Pre-funded Warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per Pre-funded Warrant. The Company received net proceeds of approximately $140.5 million, after deducting underwriting discounts and commissions and estimated offering costs. The Pre-funded Warrants associated with the February 2026 Offering have been classified as a liability and recorded at fair value with changes in fair value recorded in the condensed consolidated statements of operations and comprehensive loss.
v3.26.1
Share-Based Compensation
6 Months Ended
Jun. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation
7. Share-Based Compensation
2017 Equity Incentive Plan
Under the Company’s historical shareholder and subscription agreements, the Company was authorized to issue restricted shares, restricted share units, as well as options, as incentives to its employees, non-employees and members of its board of directors.
As of June 30, 2026, the Company was authorized to issue a total of 397,999 ordinary shares underlying outstanding options granted under the 2017 Plan prior to our initial public offering, or IPO.
2020 Employee Share Purchase Plan
The Company’s 2020 Employee Share Purchase Plan, or the ESPP, provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter through termination of the 2020 Plan, by the lesser of (i) 1% of the outstanding number of ordinary shares on the immediately preceding December 31, (ii) 510,080 ordinary shares or (iii) such lesser number of ordinary shares as determined by the plan administrator.
2020 Share Option Plan
The Company’s 2020 Share Option and Incentive Plan, or the 2020 Plan, allows the compensation and leadership development committee to make equity-based, including options and restricted share units, and cash-based incentive awards to the Company’s officers, employees, directors and other key persons (including consultants).
The Company initially reserved 2,074,325 of its ordinary shares for the issuance of awards under the 2020 Plan. The 2020 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2022, by up to 4% of the outstanding number of ordinary shares on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s compensation and leadership development committee. The total number of ordinary shares that were authorized for issuance under the 2020 Plan is 14,523,648 shares as of June 30, 2026, of which 3,656,273 shares remained available for future grant.
2022 Inducement Option Award
During 2022, the Company granted a non-qualified share option to purchase up to 600,000 ordinary shares as an inducement grant to our chief executive officer.
2026 Inducement Plan
The Company’s 2026 Inducement Plan, or the Inducement Plan, allows the compensation and leadership development committee to make equity-based awards, including options and restricted share units, exclusively to individuals who were not previously employees or directors of the Company, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market, or Rule
5635(c)(4). The Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4). The Company reserved 3,500,000 of its ordinary shares for the issuance of awards under the Inducement Plan, of which 2,910,020 shares remained available for future grant as of June 30, 2026.
Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Research and development$1,202 $1,289 $2,137 $2,813 
General and administrative2,825 2,307 4,786 4,718 
Total share-based compensation expense
$4,027 $3,596 $6,923 $7,531 
v3.26.1
Net Loss Per Share
6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Net Loss Per Share
The Company computes basic net loss per share by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company computes diluted net loss per share by dividing net loss by the weighted-average number of shares and dilutive potential share equivalents then outstanding during the period. The Company’s potentially dilutive securities, which include unvested ordinary shares, unvested restricted share units, options granted and equity-classified warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of ordinary shares outstanding used to calculate both basic and diluted net loss per share attributable to ordinary shareholders is the same.
The Company excluded the following ordinary shares subject to issuance upon the vesting of equity awards, the exercise of options and warrants outstanding at each period end and the purchase of shares under the employee share purchase plan, from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have had an anti-dilutive effect:
As of June 30,
20262025
Employee share purchase plan
35,129 40,342 
Unvested restricted share units1,522,818 946,502 
Share options9,852,870 8,427,841 
Warrants - equity-classified
11,903,92212,418,922 
Warrants - liability-classified
23,848,82946,104,168 
47,163,56867,937,775
v3.26.1
Commitments and Contingencies
6 Months Ended
Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
9. Commitments and Contingencies
Legal Proceedings
From time to time, the Company may be a party to litigation or subject to claims incident to the ordinary course of business. The Company was not a party to any material litigation and did not have material contingency reserves established for any liabilities as of June 30, 2026 or December 31, 2025.
Indemnification
In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into deeds of indemnity with its directors and officers that may require the Company to indemnify its directors and officers
against liabilities that may arise by reason of their status or service as directors or officers in accordance with the indemnification obligations under its Articles of Association. The Company currently has directors’ and officers’ insurance.
v3.26.1
Segment Reporting
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
10. Segment Reporting
The Company has one operating segment. The table below is a summary of the segment loss, including significant segment expenses (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Operating expenses:
Research and Development:
Development expenses
$19,210 $21,442 $35,454 $43,138 
Personnel expenses
6,568 6,113 13,360 12,182 
Non-cash share-based compensation expense
1,202 1,289 2,137 2,813 
Facilities and other expenses1
2,195 1,481 4,704 3,072 
General and Administrative:
Personnel expenses
8,212 4,618 13,972 9,679 
Legal and professional fees
5,878 3,367 12,405 12,731 
Facilities and other expenses1
6,282 2,316 8,458 4,216 
Non-cash share-based compensation expense
2,825 2,307 4,786 4,718 
Total operating expenses 52,372 42,933 95,276 92,549 
Loss from operations
(52,372)(42,933)(95,276)(92,549)
Fair value change of warrant liabilities
(205,577)(2,540)(74,661)16,920 
Interest income3,744 1,898 6,163 4,284 
Benefit from R&D tax credit2,583 4,287 5,060 12,735 
Interest expense(1,483)(1,151)(2,948)(2,275)
Foreign exchange (losses) gains
(904)2,349 (1,640)4,482 
Other income (expense)
546 (176)1,030 627 
Income tax expense
(331)(137)(320)(491)
Net loss
$(253,794)$(38,403)$(162,592)$(56,267)
1Other expenses include subscriptions and memberships, consulting fees and company insurance.
v3.26.1
Subsequent Events
6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]  
Subsequent Events
11. Subsequent Events
During the third-quarter of 2026, through July 30, 2026, as a result of sales of shares under our Sales Agreement with TD Cowen and upon exercise of certain warrants issued in the August 2023 PIPE, the Company received aggregate proceeds of $31.7 million and issued an aggregate of 2,690,696 ADSs.
v3.26.1
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.26.1
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2025, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair statement of the Company’s financial position for the reported periods.
The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. These interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2025, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K that was filed with the SEC, on March 24, 2026. The condensed consolidated balance sheet at December 31, 2025, was derived from audited annual consolidated financial statements but does not contain all of the footnote disclosures from the annual financial statements.
Principles of Consolidation
Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.
Use of Estimates
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, warrant liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
In November 2024, the FASB issued ASU 2024-03 - Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, designed to improve disclosures, primarily through increased expense disaggregation. Additionally, in January 2025, the FASB issued ASU 2025-01 to clarify the effective date of ASU 2024-03. The guidance is effective for all fiscal years beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The new standard can be adopted on a prospective basis with an option to be adopted retrospectively and early adoption is permitted. The Company is not early adopting the standard. We are currently evaluating this guidance to determine its impact on the Company’s consolidated financial statement disclosures.
v3.26.1
Fair Value of Financial Assets and Liabilities (Tables)
6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets Measured on Recurring Basis
The following tables present information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:
Fair Value Measurements
as of June 30, 2026
Level 1Level 2Level 3Total
Assets:
Cash equivalents - money market funds$195,032 $— $— $195,032 
$195,032 $— $— $195,032 
Liabilities:
Pre-funded Warrants
$— $337,459 $— $337,459 
$— $337,459 $— $337,459 
Fair Value Measurements
as of December 31, 2025
Level 1
Level 2
Level 3
Total
Assets:
Cash equivalents - money market funds$43,053 $— $— $43,053 
$43,053 $— $— $43,053 
Liabilities:
Pre-funded Warrants
$— $60,029 $— $60,029 
2025 ADS Warrants
— — 143,697 143,697 
$— $60,029 $143,697 $203,726 
Schedule of Fair Value of Warrant Liabilities
The following table reflects the fair value of the Company’s warrant liabilities for the six months ended June 30, 2026:
Pre-Funded Warrants
ADS Warrants
Fair value as of December 31, 2025
$60,029 $143,697 
Change in fair value of warrant liabilities140,965(66,304)
Exercise of 2025 Financing pre-funded warrant liabilities(33,719)(32,542)
Issuance of February 2026 Offering of pre-funded warrants10,000—
Conversion of 2025 Financing ADS warrants to pre-funded warrants160,184(44,851)
Fair value as of June 30, 2026
$337,459 $— 
v3.26.1
Prepaid Expenses and Other Current Assets (Tables)
6 Months Ended
Jun. 30, 2026
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following (in thousands):
June 30,December 31,
20262025
UK R&D tax credit
$15,155 $15,387 
Prepaid research and development16,074 17,102 
Prepaid income tax 2,600 3,434 
Other current assets8,125 5,580 
$41,954 $41,503 
v3.26.1
Debt (Tables)
6 Months Ended
Jun. 30, 2026
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
Long-term debt consisted of the following (in thousands):
June 30,December 31,
20262025
Term loan payable$50,000 $30,000 
End of term charge5,300 1,425 
Future principal payments and end of term charge$55,300 $31,425 
PIK interest payable— 1,088 
Unamortized debt issuance costs(4,573)(880)
Carrying value of long-term debt$50,727 $31,633 
Less: current portion
$— $(17,523)
Non-current portion
$50,727 $14,110 
Schedule of Future Principal Payments
Future principal payments, including End of Term Charge, are as follows (in thousands):
December 31, 2026$— 
December 31, 20271,425 
December 31, 2028— 
December 31, 202921,674 
December 31, 203025,975 
December 31, 20316,226 
Total$55,300 
v3.26.1
Share-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Compensation Expense
Share-based compensation expense recorded as research and development and general and administrative expenses is as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Research and development$1,202 $1,289 $2,137 $2,813 
General and administrative2,825 2,307 4,786 4,718 
Total share-based compensation expense
$4,027 $3,596 $6,923 $7,531 
v3.26.1
Net Loss Per Share (Tables)
6 Months Ended
Jun. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The Company excluded the following ordinary shares subject to issuance upon the vesting of equity awards, the exercise of options and warrants outstanding at each period end and the purchase of shares under the employee share purchase plan, from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have had an anti-dilutive effect:
As of June 30,
20262025
Employee share purchase plan
35,129 40,342 
Unvested restricted share units1,522,818 946,502 
Share options9,852,870 8,427,841 
Warrants - equity-classified
11,903,92212,418,922 
Warrants - liability-classified
23,848,82946,104,168 
47,163,56867,937,775
v3.26.1
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting The table below is a summary of the segment loss, including significant segment expenses (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Operating expenses:
Research and Development:
Development expenses
$19,210 $21,442 $35,454 $43,138 
Personnel expenses
6,568 6,113 13,360 12,182 
Non-cash share-based compensation expense
1,202 1,289 2,137 2,813 
Facilities and other expenses1
2,195 1,481 4,704 3,072 
General and Administrative:
Personnel expenses
8,212 4,618 13,972 9,679 
Legal and professional fees
5,878 3,367 12,405 12,731 
Facilities and other expenses1
6,282 2,316 8,458 4,216 
Non-cash share-based compensation expense
2,825 2,307 4,786 4,718 
Total operating expenses 52,372 42,933 95,276 92,549 
Loss from operations
(52,372)(42,933)(95,276)(92,549)
Fair value change of warrant liabilities
(205,577)(2,540)(74,661)16,920 
Interest income3,744 1,898 6,163 4,284 
Benefit from R&D tax credit2,583 4,287 5,060 12,735 
Interest expense(1,483)(1,151)(2,948)(2,275)
Foreign exchange (losses) gains
(904)2,349 (1,640)4,482 
Other income (expense)
546 (176)1,030 627 
Income tax expense
(331)(137)(320)(491)
Net loss
$(253,794)$(38,403)$(162,592)$(56,267)
1Other expenses include subscriptions and memberships, consulting fees and company insurance.
v3.26.1
Nature of Business (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]              
Net income (loss) $ (253,794) $ 91,202 $ (38,403) $ (17,864) $ (162,592) $ (56,267)  
Accumulated deficit 985,186       985,186   $ 822,594
Cash and cash equivalents $ 433,295   $ 221,881   $ 433,295 $ 221,881 $ 149,608
v3.26.1
Fair Value of Financial Assets and Liabilities - Schedule of Schedule of Fair Value, Assets Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Assets:    
Cash equivalents - money market funds $ 195,032 $ 43,053
Assets 195,032 43,053
Liabilities:    
Warrant liabilities 337,459 203,726
Liabilities 337,459 203,726
Pre-Funded Warrants    
Liabilities:    
Warrant liabilities 337,459 60,029
Liabilities 337,459 60,029
ADS Warrants    
Liabilities:    
Warrant liabilities   143,697
Liabilities 0 143,697
Level 1    
Assets:    
Cash equivalents - money market funds 195,032 43,053
Assets 195,032 43,053
Liabilities:    
Liabilities 0 0
Level 1 | Pre-Funded Warrants    
Liabilities:    
Warrant liabilities 0 0
Level 1 | ADS Warrants    
Liabilities:    
Warrant liabilities   0
Level 2    
Assets:    
Cash equivalents - money market funds 0 0
Assets 0 0
Liabilities:    
Liabilities 337,459 60,029
Level 2 | Pre-Funded Warrants    
Liabilities:    
Warrant liabilities 337,459 60,029
Level 2 | ADS Warrants    
Liabilities:    
Warrant liabilities   0
Level 3    
Assets:    
Cash equivalents - money market funds 0 0
Assets 0 0
Liabilities:    
Liabilities 0 143,697
Level 3 | Pre-Funded Warrants    
Liabilities:    
Warrant liabilities $ 0 0
Level 3 | ADS Warrants    
Liabilities:    
Warrant liabilities   $ 143,697
v3.26.1
Fair Value of Financial Assets and Liabilities - Narrative (Details) - USD ($)
$ in Millions
Jun. 30, 2026
Dec. 31, 2025
Fair Value Disclosures [Abstract]    
Cash held in notice accounts, less than 90 days $ 0.4 $ 60.8
v3.26.1
Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrant Liabilities (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Beginning balance of fair value   $ 203,726   $ 203,726  
Change in fair value of warrant liabilities $ (205,577)   $ (2,540) (74,661) $ 16,920
Ending balance of fair value 337,459     337,459  
Pre-Funded Warrants          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Beginning balance of fair value   60,029   60,029  
Change in fair value of warrant liabilities       140,965  
Exercise of 2025 Financing pre-funded warrant liabilities   (33,700)   (33,719)  
Issuance of February 2026 Offering of pre-funded warrants       10,000  
Conversion of 2025 Financing ADS warrants to pre-funded warrants       160,184  
Ending balance of fair value 337,459     337,459  
ADS Warrants          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Beginning balance of fair value   $ 143,697   143,697  
Change in fair value of warrant liabilities       (66,304)  
Exercise of 2025 Financing pre-funded warrant liabilities       (32,542)  
Issuance of February 2026 Offering of pre-funded warrants       0  
Conversion of 2025 Financing ADS warrants to pre-funded warrants       (44,851)  
Ending balance of fair value $ 0     $ 0  
v3.26.1
Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
UK R&D tax credit $ 15,155 $ 15,387
Prepaid research and development 16,074 17,102
Prepaid income tax 2,600 3,434
Other current assets 8,125 5,580
Prepaid expense and other current assets $ 41,954 $ 41,503
v3.26.1
Prepaid Expenses and Other Current Assets - Narrative (Details) - USD ($)
$ in Millions
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]      
R&D tax credit, potential receivable $ 7.3 $ 7.0 $ 4.1
v3.26.1
Debt - Narrative (Details)
$ in Millions
6 Months Ended
Jan. 05, 2026
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2023
Jun. 30, 2023
USD ($)
shares
Debt Instrument [Line Items]          
Number of shares available for purchase, percent of principal amount of term loan (as a percent)       0.025 0.025
Number of options exercisable (in shares) | shares         94,222
Fair value of exercisable options         $ 0.7
Debt interest expense   $ 2.9 $ 2.3    
Loan Agreement          
Debt Instrument [Line Items]          
Convertible notes, face amount         50.0
Convertible notes interest (as a percent) 9.75%        
Interest rate, prime margin (as a percent) 2.75%        
Fees and transaction costs   3.3      
Loan Agreement | Facility Fees          
Debt Instrument [Line Items]          
Fees and transaction costs   0.4      
Loan Agreement | Company Fees          
Debt Instrument [Line Items]          
Fees and transaction costs   0.8      
Loan Agreement | Warrant Fees          
Debt Instrument [Line Items]          
Fees and transaction costs   0.7      
Loan Agreement | End of Term Charge          
Debt Instrument [Line Items]          
Fees and transaction costs   1.4      
Loan Agreement, Term Loan One          
Debt Instrument [Line Items]          
Convertible notes, face amount         $ 30.0
Amended Loan Agreement          
Debt Instrument [Line Items]          
Convertible notes, face amount $ 150.0        
Repayments of debt 31.1        
Fees and transaction costs   $ 4.2      
Effective interest rate   12.90%      
Debt instrument covenant, cash on hand, percent   55.00%      
Market capitalization   $ 850.0      
Amended Loan Agreement | Facility Fees          
Debt Instrument [Line Items]          
Fees and transaction costs   0.3      
Amended Loan Agreement | End of Term Charge          
Debt Instrument [Line Items]          
Fees and transaction costs   $ 3.9      
Amended Loan Agreement, Term Loan One          
Debt Instrument [Line Items]          
Borrowed in drawings of a minimum 5.0        
Amended Loan Agreement, Term Loan One | Debt Instrument, Redemption, Period One          
Debt Instrument [Line Items]          
Convertible notes, face amount 50.0        
Amended Loan Agreement, Term Loan One | Debt Instrument, Redemption, Period Two          
Debt Instrument [Line Items]          
Convertible notes, face amount 30.0        
Amended Loan Agreement, Term Loan One | Debt Instrument, Redemption, Period Three          
Debt Instrument [Line Items]          
Convertible notes, face amount 20.0        
Amended Loan Agreement, Term Loan One | Debt Instrument, Redemption, Period Four          
Debt Instrument [Line Items]          
Convertible notes, face amount 20.0        
Amended Loan Agreement, Term Loan One | Debt Instrument, Redemption, Period Five          
Debt Instrument [Line Items]          
Convertible notes, face amount $ 30.0        
v3.26.1
Debt - Schedule of Components of Debt (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Debt Disclosure [Abstract]    
Term loan payable $ 50,000 $ 30,000
End of term charge 5,300 1,425
Future principal payments and end of term charge 55,300 31,425
PIK interest payable 0 1,088
Unamortized debt issuance costs (4,573) (880)
Carrying value of long-term debt 50,727 31,633
Less: current portion 0 (17,523)
Non-current portion $ 50,727 $ 14,110
v3.26.1
Debt - Schedule of Principal Payments (Details) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Debt Disclosure [Abstract]    
December 31, 2026 $ 0  
December 31, 2027 1,425  
December 31, 2028 0  
December 31, 2029 21,674  
December 31, 2030 25,975  
December 31, 2031 6,226  
Future principal payments and end of term charge $ 55,300 $ 31,425
v3.26.1
Shareholders’ Equity/(Deficit) (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 16 Months Ended 34 Months Ended 41 Months Ended
Feb. 19, 2026
USD ($)
$ / shares
shares
Jan. 13, 2025
USD ($)
shares
Aug. 18, 2023
$ / shares
shares
Oct. 08, 2021
USD ($)
Feb. 28, 2026
USD ($)
shares
Mar. 31, 2026
USD ($)
shares
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2026
£ / shares
shares
Jun. 30, 2026
USD ($)
shares
Feb. 27, 2025
USD ($)
shares
Jan. 13, 2025
£ / shares
shares
Jan. 13, 2025
$ / shares
shares
Feb. 29, 2024
Dec. 31, 2023
Jun. 30, 2023
USD ($)
shares
Class of Stock [Line Items]                                  
Ordinary share conversion ratio (in shares)       1                          
Number of shares available for purchase, percent of principal amount of term loan (as a percent)                               0.025 0.025
Number of options exercisable (in shares) | shares                                 94,222
Fair value of exercisable options                                 $ 700
Proceeds from issuance of pre-funded warrants associated with the 2025 Offering, net of issuance costs             $ 1 $ 0                  
PIPE Warrants                                  
Class of Stock [Line Items]                                  
Warrant exercise price (in dollars per share) | $ / shares     $ 9.93                            
Issuance of ordinary shares to settle warrant exercised (in shares) | shares             515,000       4,267,050            
Proceeds from the exercise of ADS warrants             $ 5,114     $ 42,400            
Proceeds from warrant exercises, fully exercised             117,300                    
ADS Warrants                                  
Class of Stock [Line Items]                                  
Proceeds from issuance of pre-funded warrants associated with the 2025 Offering, net of issuance costs   $ 149,800                              
Issuance costs of warrant   $ 9,400                              
Issuance of February 2026 Offering of pre-funded warrants             32,542                    
Pre-Funded Warrants                                  
Class of Stock [Line Items]                                  
Issuance of February 2026 Offering of pre-funded warrants           $ 33,700 $ 33,719                    
PIPE warrants remain outstanding | shares             23,848,829   23,848,829 23,848,829 23,848,829            
Hercules Capital, Inc.                                  
Class of Stock [Line Items]                                  
Term (in years)                                 10 years
Number of options exercisable (in shares) | shares                                 94,222
Fair value of exercisable options                                 $ 700
At-The-Market Offering                                  
Class of Stock [Line Items]                                  
Sale of stock, shares issued in transaction (in shares) | shares                 108,000     5,491,836          
Consideration received on transaction                 $ 1,400     $ 54,800          
Sale of stock, average price per share (in dollars per share) | £ / shares                   £ 13.2649              
Private Placement                                  
Class of Stock [Line Items]                                  
Ordinary share conversion ratio (in shares)     1                            
Sale of stock, shares issued in transaction (in shares) | shares     16,076,750                            
Sale of stock, price per share (in dollars per share) | $ / shares     $ 7.78                            
Private Placement | PIPE Warrants                                  
Class of Stock [Line Items]                                  
Term (in years)                             3 years    
Underwritten Offering                                  
Class of Stock [Line Items]                                  
Sale of stock, shares issued in transaction (in shares) | shares         15,160,619                        
Consideration received on transaction $ 140,500                                
Underwritten Offering | ADS Warrants                                  
Class of Stock [Line Items]                                  
Ordinary share conversion ratio (in shares)   1                              
Sale of stock, shares issued in transaction (in shares) | shares   24,014,728                              
Sale of stock, price per share (in dollars per share) | (per share)                         £ 0.008 $ 4.2750      
Warrant exercise price (in dollars per share) | $ / shares                           $ 5.7960      
Issuance of ordinary shares to settle warrant exercised (in shares) | shares         35,059,448                        
Purchase of warrants (in shares) | shares         19,898,829               24,014,728 24,014,728      
Proceeds from issuance and exercises of warrants         $ 203,200                        
Underwritten Offering | Pre-Funded Warrants                                  
Class of Stock [Line Items]                                  
Sale of stock, price per share (in dollars per share) | $ / shares $ 7.9999                         $ 4.2649      
Warrant exercise price (in dollars per share) | $ / shares                           $ 0.0001      
Purchase of warrants (in shares) | shares 1,250,000                       11,044,720 11,044,720      
Warrants exercised (in shares) | shares           6,000,000                      
Underwritten Offering | 2026 ADS Warrants                                  
Class of Stock [Line Items]                                  
Ordinary share conversion ratio (in shares) 1                                
Sale of stock, shares issued in transaction (in shares) | shares 17,500,000                                
Sale of stock, price per share (in dollars per share) | $ / shares $ 8.00                                
American Depositary Shares | Initial Public Offering                                  
Class of Stock [Line Items]                                  
Amount authorized       $ 150,000                          
American Depositary Shares | At-The-Market Offering                                  
Class of Stock [Line Items]                                  
Amount authorized                       $ 150,000          
v3.26.1
Share-Based Compensation - 2017 Equity Incentive Plan (Details)
Jun. 30, 2026
shares
Employee Stock Option | 2017 Equity Incentive Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares authorized (in shares) 397,999
v3.26.1
Share-Based Compensation - 2020 Employee Share Purchase Plan (Details) - Employee stock
6 Months Ended
Jun. 30, 2026
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Allowable increase in shares authorized for issuance, percentage of outstanding stock (as a percent) 1.00%
Maximum increase in shares available for issuance (in shares) 510,080
v3.26.1
Share-Based Compensation - 2020 Share Option Plan (Details) - shares
Jun. 30, 2026
Jan. 01, 2022
Employee stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares available for grant (in shares) 3,656,273  
2020 Share Option Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares issued (in shares) 14,523,648  
2020 Share Option Plan | Ordinary shares    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares reserved for future issuance (in shares) 2,074,325  
Maximum percentage of shares outstanding number of shares reserved for issuance may increase (as a percent)   4.00%
v3.26.1
Share-Based Compensation - 2022 Inducement Option Award (Details)
Dec. 31, 2022
shares
2022 Inducement Grant Option Award | Ordinary shares  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares available for grant (in shares) 600,000
v3.26.1
Share-Based Compensation - 2026 Inducement Plan (Details) - 2026 Inducement Plan - Ordinary shares
Jun. 30, 2026
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares reserved for future issuance (in shares) 3,500,000
Number of shares available for grant (in shares) 2,910,020
v3.26.1
Share-Based Compensation - Schedule of Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 4,027 $ 3,596 $ 6,923 $ 7,531
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense 2,825 2,307 4,786 4,718
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 1,202 $ 1,289 $ 2,137 $ 2,813
v3.26.1
Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 47,163,568,000 67,937,775,000
Employee share purchase plan    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 35,129,000 40,342,000
Unvested restricted share units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 1,522,818,000 946,502,000
Share options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 9,852,870,000 8,427,841,000
Warrants - equity-classified    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 11,903,922,000 12,418,922,000
Warrants - liability-classified    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 23,848,829,000 46,104,168,000
v3.26.1
Segment Reporting (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Abstract]            
Number of operating segments | segment         1  
Number Of Reportable Segments Not Disclosed Flag         true  
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items]            
Research and development $ 29,175   $ 30,325   $ 55,655 $ 61,205
General and administrative 23,197   12,608   39,621 31,344
Total operating expenses 52,372   42,933   95,276 92,549
Loss from operations: (52,372)   (42,933)   (95,276) (92,549)
Fair value change of warrant liabilities (205,577)   (2,540)   (74,661) 16,920
Interest income 3,744   1,898   6,163 4,284
Benefit from R&D tax credit 2,583   4,287   5,060 12,735
Interest expense (1,483)   (1,151)   (2,948) (2,275)
Foreign exchange (losses) gains (904)   2,349   (1,640) 4,482
Other income (expense) 546   (176)   1,030 627
Income tax expense (331)   (137)   (320) (491)
Net loss (253,794) $ 91,202 (38,403) $ (17,864) (162,592) (56,267)
Single Operating Segment            
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items]            
Total operating expenses 52,372   42,933   95,276 92,549
Loss from operations: (52,372)   (42,933)   (95,276) (92,549)
Fair value change of warrant liabilities (205,577)   (2,540)   (74,661) 16,920
Interest income 3,744   1,898   6,163 4,284
Benefit from R&D tax credit 2,583   4,287   5,060 12,735
Interest expense (1,483)   (1,151)   (2,948) (2,275)
Foreign exchange (losses) gains (904)   2,349   (1,640) 4,482
Other income (expense) 546   (176)   1,030 627
Income tax expense (331)   (137)   (320) (491)
Net loss (253,794)   (38,403)   (162,592) (56,267)
Development expenses | Single Operating Segment            
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items]            
Research and development 19,210   21,442   35,454 43,138
Personnel expenses | Single Operating Segment            
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items]            
Research and development 6,568   6,113   13,360 12,182
General and administrative 8,212   4,618   13,972 9,679
Non-cash share-based compensation expense | Single Operating Segment            
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items]            
Research and development 1,202   1,289   2,137 2,813
General and administrative 2,825   2,307   4,786 4,718
Facilities and other expenses | Single Operating Segment            
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items]            
Research and development 2,195   1,481   4,704 3,072
General and administrative 6,282   2,316   8,458 4,216
Legal and professional fees | Single Operating Segment            
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Line Items]            
General and administrative $ 5,878   $ 3,367   $ 12,405 $ 12,731
v3.26.1
Subsequent Events (Details) - PIPE Warrants - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended 34 Months Ended
Jul. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Subsequent Event [Line Items]        
Proceeds from the exercise of warrants   $ 5,114 $ 42,400
Issuance of ordinary shares to settle warrant exercised (in shares)   515,000   4,267,050
Subsequent event        
Subsequent Event [Line Items]        
Proceeds from the exercise of warrants $ 31,700      
Issuance of ordinary shares to settle warrant exercised (in shares) 2,690,696